Vertex Pharmaceuticals Inc (VRTX) - News Archive

Vertex Pharmaceuticals announced today that its drug KALYDECO (ivacaftor) has received approval from the European Commission for label expansion, allowing its use for infants with cystic fibrosis (CF) aged one month and...

LONDON - In a significant development for cystic fibrosis (CF) treatment, Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the European Commission (EC) has approved the use of KALYDECO (ivacaftor) for the trea...

Vertex Pharmaceuticals, a renowned biopharmaceutical company, announced today that their drug, KALYDECO (ivacaftor), has been granted approval by the European Commission for expanded use in infants as young as one month...

Vertex Pharmaceuticals, a renowned biotechnology company, has received approval from the European Commission for the expanded use of their drug, KALYDECO (ivacaftor), in treating infants as young as one month old with c...